J3055 Injection talquetamab-tgvs 0.25 milligrams
Also known as: talquetamab, Tecvayli, bispecific T-cell engager
Talquetamab-tgvs (Tecvayli) 0.25 milligram injection is a bispecific T-cell engager monoclonal antibody used for the treatment of relapsed or refractory multiple myeloma.
In Plain Language
multiple myeloma treatment; cancer-fighting protein injection
Clinical Context
Indicated for relapsed/refractory multiple myeloma patients. Engages T-cells to target malignant plasma cells. Administered intravenously with careful monitoring for cytokine release syndrome and other immune-related adverse events.
RVU Information
CPT J3055 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3055?
CPT J3055 (Injection talquetamab-tgvs 0.25 milligrams) is a J Codes (Drugs) code. Talquetamab-tgvs (Tecvayli) 0.25 milligram injection is a bispecific T-cell engager monoclonal antibody used for the treatment of relapsed or refractory multiple myeloma.
How is J3055 administered?
CPT J3055 is administered by a healthcare provider, typically via injection or infusion. Indicated for relapsed/refractory multiple myeloma patients. Engages T-cells to target malignant plasma cells. Administered intravenously with careful monitoring for cytokine release syndrome and other immune-related adverse events. It is used by Hematology/Oncology, Infusion Centers, Internal Medicine.
When is CPT J3055 used?
Indicated for relapsed/refractory multiple myeloma patients. Engages T-cells to target malignant plasma cells. Administered intravenously with careful monitoring for cytokine release syndrome and other immune-related adverse events.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.